Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mike Ward

London, UK
Mike has been writing, analysing and commenting on the life sciences industry for more than 30 years as a journalist and investment bank analyst. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry's key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year and has appeared on the shortlist for that award on numerous occasions. When not commentating on all things pharma, Mike is engaged actively in pub quizzes, either as a competitor or a compiler. He is also a qualified FA soccer coach.
Advertisement
Set Alert for Articles By Mike Ward

Latest From Mike Ward

Finance Watch: Former GSK CEO Witty, R&D Head Slaoui Join VC Firms

Medicxi's new $300m venture fund will benefit from the expertise of former GSK R&D leader Moncef Slaoui, while ex-CEO Witty will inform portfolio strategy at Hatteras. Also, Kaleido hires past Cubist CEO and brings VC funding to $65m, while Gilead sells $3bn in debt to fund Kite deal.

Leadership Financing

Versant & MPM Back Synthetic Lethality Newco With $68M

Repare Therapeutics Inc., a Boston and Toronto-based cancer biotech, focusing on synthetic lethality, has hit the ground running with a $68m series A round from seasoned venture capitalists.

Financing Companies

BIO Notebook, Day 2: Deal Insights, A Payer Perspective And EMA Rumors

In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.

Deals Business Strategies

Midsummer Madness: EMA Headquarters Rumors Fly At BIO

The biotech industry's annual confab, already known as a stage for countries and regions to play up their potential as industry hubs, is now the venue for rumors over who will host the headquarters for the European Medicines Agency post-Brexit.

Brexit Regulation

Google Joins Novartis Backing Medicxi’s New $300m Late-Stage Fund

Alphabet's Verily Life Sciences intends to increase its exposure to European biotech by joining Novartis and the European Investment Fund as cornerstone investors in Medicxi Growth 1 (MG1), a $300m fund launched by VC firm Medicxi to focus on late-stage private life science companies.

Business Strategies Commercial
See All
Advertisement
UsernamePublicRestriction

Register